Press releases - GSK
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK Says Potential Blockbuster Helps Treat Common Nasal Disease
Oct 14, 2024 · GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. ... news and insight ...
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract …
Oct 16, 2024 · On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...
Press releases | GSK US
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024 60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Gepotidacin accepted for priority review by US FDA for treatment ... - GSK
Oct 16, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for the treatment of female adults (≥40 kg) and adolescents (≥12 years, ≥40 kg) with uncomplicated urinary ...
GSK readies for pivotal ruling in Zantac cases - Financial Times
Apr 24, 2024 · GSK points to subsequent research by the FDA, EMA and other scientists that have failed to establish a causal association between their drug and cancer.
GSK boosts respiratory portfolio with $1.4 bln Aiolos Bio deal
Jan 9, 2024 · GSK on Tuesday said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio.
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · Emma Walmsley, Chief Executive Officer, GSK: "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines.
GSK set to face jury trials over heartburn drug Zantac - Financial Times
Jun 1, 2024 · GSK and other pharmaceutical groups are set to face jury trials in cases brought by more than 72,000 cancer sufferers who allege a heartburn drug caused their condition, after a judge in Delaware...
GSK raises profit outlook on strong vaccine, HIV drug sales
May 1, 2024 · GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.